Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL-II
2011-005740-95Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paritaprevir, ritonavir, glecaprevir, dasabuvir and ribavirin in chronic hepatitis C (CHC) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Safety of 12 weeks of treatment and SVR12 non-inferiority versus historical control. Started Jul 2012; status: completed.
02
Drugs
paritaprevirritonavirglecaprevirdasabuvirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2011-005740-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005740-95.